Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28601574 | 0.81 | CYP1A2 (0.37) | CYP1A2TSHRTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17376821 | 0.74 | CPN1 (0.45) | CYP1A2TSHRTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16249740 | 0.74 | CPN1 (0.45) | CYP1A2TSHRTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27598543 | 0.71 | ALDH1A1 (0.47) | CYP1A2TSHRTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13115586 | 0.71 | ALDH1A1 (0.52) | CYP1A2TSHRTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL258779 | 0.69 | ALDH1A1 (0.55) | CYP1A2TSHRGRIK1TDP1SMN1; SMN2 | |
| SCHEMBL8133196 | 0.69 | ALDH1A1 (0.55) | CYP1A2TSHRGRIK1TDP1SMN1; SMN2 | |
| SCHEMBL6756443 | 0.69 | ALDH1A1 (0.55) | CYP1A2TSHRGRIK1TDP1SMN1; SMN2 | |
| SCHEMBL28167338 | 0.69 | CYP1A2 (0.36) | CYP1A2TSHRLMNATDP1ALDH1A1 | |
| SCHEMBL28968533 | 0.68 | ALDH1A1 (0.53) | CYP1A2TSHRGRIK1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658796-B2 | Complexes of ruthenium, method of production thereof and use thereof as (pre)catalysts of the metathesis reaction | UMICORE AG & CO. KG (DE) | 2014-02-25 | — | — | US | disclosed |
| US-20130079515-A1 | Complexes of Ruthenium, Method of Production Thereof And Use Thereof As (Pre)Catalysts of the Metathesis Reaction | UMICORE AG & CO. KG (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8318965-B2 | Complex of ruthenium, method of production thereof and use thereof as (pre)catalysts of the metathesis reaction | UMICORE AG & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20100174068-A1 | Complex of Ruthenium and Osmium, Method of Production Thereof and Use Thereof As (Pre)Catalysts of the Metathesis Reaction | UMICORE AG & CO KG (DE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079515-A1 | Complexes of Ruthenium, Method of Production Thereof And Use Thereof As (Pre)Catalysts of the Metathesis Reaction | CBR3, CBR1, C1R | CYP1A2 631/4885TSHR 233/4885FOLH1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.